GSK (GSK) Projected to Post Earnings on Tuesday

GSK (NYSE:GSK) is projected to announce its Q2 2026 results before the market opens on Tuesday, July 28th. Analysts expect GSK to announce earnings of $1.27 per share and revenue of $11.0198 billion for the quarter. Investors can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, July 28, 2026 at 9:00 AM ET.

GSK Price Performance

Shares of GSK stock opened at $51.38 on Monday. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.79 and a quick ratio of 0.52. The business’s 50 day simple moving average is $51.58 and its two-hundred day simple moving average is $53.42. The stock has a market capitalization of $103.92 billion, a P/E ratio of 13.35, a price-to-earnings-growth ratio of 3.27 and a beta of 0.35. GSK has a one year low of $36.75 and a one year high of $61.69.

GSK Cuts Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, July 9th. Stockholders of record on Friday, May 15th were paid a dividend of $0.44 per share. This represents a $1.76 dividend on an annualized basis and a dividend yield of 3.4%. The ex-dividend date of this dividend was Friday, May 15th. GSK’s dividend payout ratio is 46.49%.

Trending Headlines about GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: The FDA approved Jideytro for previously treated ROS1-positive non-small cell lung cancer, marking GSK’s first lung cancer approval and a new catalyst for its oncology pipeline. Article
• Positive Sentiment: Analysts and market commentary highlighted Jideytro’s approval as potentially undervalued, suggesting investors may be underestimating the earnings contribution from GSK’s precision oncology assets. Article
• Positive Sentiment: GSK also received approval in Canada for a prefilled syringe presentation of Shingrix, which should support vaccine convenience and commercial execution. Article
• Neutral Sentiment: Citigroup reaffirmed its neutral rating on GSK, indicating the approval news is positive but not enough to change the bank’s stance yet. Article

Hedge Funds Weigh In On GSK

Hedge funds have recently made changes to their positions in the business. Ameriprise Financial Inc. raised its holdings in shares of GSK by 1.2% during the second quarter. Ameriprise Financial Inc. now owns 401,777 shares of the pharmaceutical company’s stock valued at $15,444,000 after acquiring an additional 4,855 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S lifted its stake in GSK by 28.2% in the second quarter. BI Asset Management Fondsmaeglerselskab A S now owns 121,249 shares of the pharmaceutical company’s stock worth $4,656,000 after acquiring an additional 26,685 shares during the period. Align Financial LLC bought a new stake in GSK in the fourth quarter valued at $5,628,000. Arkadios Wealth Advisors boosted its holdings in GSK by 59.0% in the fourth quarter. Arkadios Wealth Advisors now owns 107,379 shares of the pharmaceutical company’s stock valued at $5,266,000 after acquiring an additional 39,863 shares in the last quarter. Finally, Captrust Financial Advisors boosted its holdings in GSK by 11.0% in the second quarter. Captrust Financial Advisors now owns 85,080 shares of the pharmaceutical company’s stock valued at $3,267,000 after acquiring an additional 8,432 shares in the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

GSK has been the topic of several recent analyst reports. Jefferies Financial Group upgraded shares of GSK to a “strong-buy” rating in a report on Friday, July 17th. Royal Bank Of Canada reiterated an “outperform” rating on shares of GSK in a report on Tuesday, June 9th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of GSK in a research report on Thursday, July 9th. Weiss Ratings lowered shares of GSK from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, June 11th. Finally, Citigroup restated a “neutral” rating on shares of GSK in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, five have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $53.00.

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.